Celldex Therapeutics
CLDX
163 hedge funds and large institutions have $1.48B invested in Celldex Therapeutics in 2014 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 63 increasing their positions, 36 reducing their positions, and 18 closing their positions.
100% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 18
75% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 36
44% more capital invested
Capital invested by funds: $1.03B → $1.48B (+$450M)
10% more funds holding
Funds holding: 148 → 163 (+15)
48% less call options, than puts
Call options by funds: $19.3M | Put options by funds: $36.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.8M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$18.3M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
+$10.3M |
| 4 |
CCI
Columbus Circle Investors
|
+$8.66M |
| 5 |
O
OppenheimerFunds
New York
|
+$7.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$39.2M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$10.9M |
| 3 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$7.32M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$6.59M |
| 5 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$6.21M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DTL
176
Dynamic Technology Lab
Singapore
| – | -$140K | -720 | Closed |
|
|
HCM
177
Highlander Capital Management
Short Hills,
New Jersey
| – | -$90.7K | -467 | Closed |
|
|
JT
178
Jump Trading
Chicago,
Illinois
| – | -$24K | -125 | Closed |
|
179
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$2K | -9 | Closed |
|
|
PTC
180
Private Trust Company
Cleveland,
Ohio
| – | -$1K | -4 | Closed |
|
CLDX Hedge Fund Activity: Q4 2014 in Review
163 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2014, worth a combined $1.48B — up 44% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new CLDX positions and 18 closed out — a net gain of 18 holders — while 63 added to existing stakes and 36 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $22.8M. The largest seller was Jennison Associates, exiting entirely with an estimated $39.2M sold.
- 163 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2014, up from 148 in Q3 2014.
- Funds reported $1.48B of Celldex Therapeutics stock for Q4 2014, up 44% quarter-over-quarter.
- 36 funds opened new Celldex Therapeutics positions in Q4 2014 and 18 closed out, a net change of +18 holders.
- The largest Celldex Therapeutics buyer in Q4 2014 was Fidelity Investments, an estimated $22.8M added.
- The largest Celldex Therapeutics seller in Q4 2014 was Jennison Associates, an estimated $39.2M sold.
Based on aggregated 13F filings for Q4 2014.